Trending...
- California: Governor Newsom, Superintendent Thurmond announce over $618 million to support another 458 community schools
- $4.3 Million Patent Application Waiver Fee Granted by FDA on New Drug Application Fee for Treatment Addressing Suicidal Depression & PTSD: NRX Pharma
- xREnergy up as much as +3,094,634% on first day listed on the XRP Ledger. Ticker : $XRE
VANCOUVER, British Columbia - Californer -- Allergan Aesthetics, a subsidiary of AbbVie Inc., a global biopharmaceutical company, has signed a licensing deal with Sirona Biochem (TSX-V: SBM). The deal is for the use of Sirona's patented library of compounds, including its breakthrough dark spot corrector molecule known as TFC-1067. AbbVie plans to commercialize and market the ingredient and add it to its growing aesthetics and cosmetics portfolio.
The global exclusive licensing agreement includes up-front payments from AbbVie to Sirona Biochem. It also includes milestone payments and royalty payments for sales generated from commercial products using Sirona's patents. AbbVie and Sirona are expected to sign a separate definitive supply agreement, which will see the latter become a major supplier of the patented compounds.
More on The Californer
AbbVie, through its subsidiary Allergan Aesthetics, controls a large portion of the global aesthetics market. The company, one of the top five pharmaceutical companies in the world based on revenue, plans to capitalize on Sirona Biochem's TFC-1067 compound, which is expected to replace hydroquinone as the next gold standard for creating an even skin tone.
The deal is part of Abbie's ongoing mission to discover and deliver new and innovative medicines to address tomorrow's medical challenges. Apart from its products and services offered through Allergan Aesthetics, AbbVie also boasts impactful products in key areas such as immunology, oncology, neuroscience, eye care, virology, women's health, and gastroenterology.
Sirona Biochem's CEO, Howard Verrico, said clinical trials of TFC-1067 had found it to be safer and more effective at treating hyperpigmentation, dark spots, and melasma compared to any other ingredient on the market.
Dr. Linda Pullan of Pullan Consulting said the deal presents an enormous opportunity for both companies as it combines AbbVie's global presence and Sirona Biochem's disruptive technology. She added that Sirona Biochem stands to generate steady income from the deal on top of the milestone and upfront payments.
More on The Californer
AbbVie and Sirona Biochem did not disclose other details of the deal as per their signed standard contractual terms. However, Sirona Biochem likely stands to gain substantial income from annual royalty payments once AbbVie is able to solidify its presence in the $8 billion global skin-lightening market.
Sirona's current pipeline includes cell preservation and repair treatments, keloid therapy, scar therapy, anti-aging, anti-wrinkle, and cellulite treatment. Sirona Biochem is also currently focused on developing a treatment for diabetic animals and a novel anti-viral treatment for humans. TFChem, Sirona's scientific development branch in France, has won several scientific accolades and European Union and French government grants.
For more information, please visit https://www.sironabiochem.com
or download their Investor's Presentation
The global exclusive licensing agreement includes up-front payments from AbbVie to Sirona Biochem. It also includes milestone payments and royalty payments for sales generated from commercial products using Sirona's patents. AbbVie and Sirona are expected to sign a separate definitive supply agreement, which will see the latter become a major supplier of the patented compounds.
More on The Californer
- OGN INVESTIGATION NOTICE: Investigation Launched into Organon & Co. and Attorneys Encourage Investors with Substantial Losses or Witnesses with Relevant Information to Contact Law Firm
- San Diego Author Debuts Thrilling Time-Travel Novel
- Bennett Awards Designs Two Cohesive Custom Awards for 2025 Sci-Tech Academy Awards
- Poll Finds Overwhelming Opposition to Keeping Big Cats as Pets
- SM Telecom Expands AT&T Partnership to Deliver Cutting-Edge 5G+ Wireless Solutions New Collab Brings AT&T's Advanced 5G+ Technology to Cellphone
AbbVie, through its subsidiary Allergan Aesthetics, controls a large portion of the global aesthetics market. The company, one of the top five pharmaceutical companies in the world based on revenue, plans to capitalize on Sirona Biochem's TFC-1067 compound, which is expected to replace hydroquinone as the next gold standard for creating an even skin tone.
The deal is part of Abbie's ongoing mission to discover and deliver new and innovative medicines to address tomorrow's medical challenges. Apart from its products and services offered through Allergan Aesthetics, AbbVie also boasts impactful products in key areas such as immunology, oncology, neuroscience, eye care, virology, women's health, and gastroenterology.
Sirona Biochem's CEO, Howard Verrico, said clinical trials of TFC-1067 had found it to be safer and more effective at treating hyperpigmentation, dark spots, and melasma compared to any other ingredient on the market.
Dr. Linda Pullan of Pullan Consulting said the deal presents an enormous opportunity for both companies as it combines AbbVie's global presence and Sirona Biochem's disruptive technology. She added that Sirona Biochem stands to generate steady income from the deal on top of the milestone and upfront payments.
More on The Californer
- Governor Newsom proclaims Older Californians Month
- Groundbreaking Launches 154-Acre Los Cerritos Wetlands Restoration in Long Beach – Single Largest Increase in Open Space in Long Beach in Decades
- Don Barnhart Drops Unapologetically Hilarious Comedy Special "You Do You," On Open Bar Network
- Cygnet Theatre Announces The Cast and Creative Team of Rodgers and Hammerstein's Oklahoma!
- Shon Garage Door Repair Expands Trusted Services to San Diego, CA
AbbVie and Sirona Biochem did not disclose other details of the deal as per their signed standard contractual terms. However, Sirona Biochem likely stands to gain substantial income from annual royalty payments once AbbVie is able to solidify its presence in the $8 billion global skin-lightening market.
Sirona's current pipeline includes cell preservation and repair treatments, keloid therapy, scar therapy, anti-aging, anti-wrinkle, and cellulite treatment. Sirona Biochem is also currently focused on developing a treatment for diabetic animals and a novel anti-viral treatment for humans. TFChem, Sirona's scientific development branch in France, has won several scientific accolades and European Union and French government grants.
For more information, please visit https://www.sironabiochem.com
or download their Investor's Presentation
Source: Sirona Biochem Corp.
Filed Under: Medical
0 Comments
Latest on The Californer
- NBA Champion Lamar Odom Launches Anti-Addiction Meme Coin, Ushering in a Disruptive Innovation in Web3
- Emmetra Partners with Renesas to Advance Agentic AI-Powered Imaging Solutions
- Gravity to Bring 5-Minute EV Charging to 8 Sites Across Greater LA
- California: Governor Newsom issues statement on Pope Leo XIV, the first American Pope
- New poll shows high rates of employee burnout amid concerns over politics and personal finances
- Tessellations Appoints Luthern Williams as Head of School
- Aureli Construction Sets the Standard for Seamless Home Additions in Greater Boston
- Psychological Thriller "Killing Off Connor" To Open 34th IFS Film Fest After 12-years In Post
- Harvest Properties Acquires Two San Francisco Bay Area Self Storage Facilities for $44.2 Million
- California businesses in near-universal compliance with prohibition of intoxicating hemp products harmful to youth
- California: Governor Newsom announces upgrades to 21 state fish hatcheries to boost salmon populations
- Solaris Energy Infrastructure, Inc. (SEI) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
- Risk Rater, Threat Assessment App, gives Users the Same Threat Evaluation as the Rich and Powerful
- Is it Really True That Tariffs Will Raise Car Insurance Rates?
- ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
- Coastal Business Systems Wraps Up Successful 2025 Tech Show in Redding
- AdOcto Turns AirBnBs Into High-Impact Advertising Channels
- Zefr Announces Launch of Pre-Screen Brand Safety Solution for Google's Search Partner Network (SPN)
- Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
- Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving